Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Stride to replace Omnicell in S&P 600 at open on 7/5  17:20
06/28/22
06/28
17:20
06/28/22
17:20
LRN

Stride

$37.71 /

+0.11 (+0.29%)

, OMCL

Omnicell

$120.33 /

-3.74 (-3.01%)

 
ShowHide Related Items >><<
OMCL Omnicell
$120.33 /

-3.74 (-3.01%)

LRN Stride
$37.71 /

+0.11 (+0.29%)

LRN Stride
$37.71 /

+0.11 (+0.29%)

04/21/22 Citi
Citi remains buyer of Stride with $65 price target
04/20/22 Barrington
Stride price target raised to $50 from $45 at Barrington
09/14/21
Fly Intel: Top five analyst initiations
09/14/21 Citi
Stride initiated with a Buy at Citi
OMCL Omnicell
$120.33 /

-3.74 (-3.01%)

06/16/22 Wells Fargo
Samsung procurement order halt 'positive' for Omnicell, says Wells Fargo
05/03/22 Wells Fargo
Omnicell price target lowered to $158 from $188 at Wells Fargo
05/02/22 Piper Sandler
Omnicell price target lowered to $162 from $181 at Piper Sandler
02/16/22 Wells Fargo
Omnicell price target lowered to $188 from $203 at Wells Fargo
OMCL Omnicell
$120.33 /

-3.74 (-3.01%)

LRN Stride
$37.71 /

+0.11 (+0.29%)

OMCL Omnicell
$120.33 /

-3.74 (-3.01%)

LRN Stride
$37.71 /

+0.11 (+0.29%)

LRN Stride
$37.71 /

+0.11 (+0.29%)

Hot Stocks
Omnicell to replace Coherent in S&P 400 at open on 7/5 » 17:19
06/28/22
06/28
17:19
06/28/22
17:19
OMCL

Omnicell

$120.33 /

-3.74 (-3.01%)

, COHR

Coherent

$268.27 /

+0.14 (+0.05%)

, IIVI

II-VI

$53.29 /

-2.8 (-4.99%)

II-VI (IIVI) is acquiring…

II-VI (IIVI) is acquiring Coherent (COHR) in a deal expected to be completed on July 1, pending final closing conditions.

ShowHide Related Items >><<
OMCL Omnicell
$120.33 /

-3.74 (-3.01%)

IIVI II-VI
$53.29 /

-2.8 (-4.99%)

COHR Coherent
$268.27 /

+0.14 (+0.05%)

OMCL Omnicell
$120.33 /

-3.74 (-3.01%)

06/16/22 Wells Fargo
Samsung procurement order halt 'positive' for Omnicell, says Wells Fargo
05/03/22 Wells Fargo
Omnicell price target lowered to $158 from $188 at Wells Fargo
05/02/22 Piper Sandler
Omnicell price target lowered to $162 from $181 at Piper Sandler
02/16/22 Wells Fargo
Omnicell price target lowered to $188 from $203 at Wells Fargo
COHR Coherent
$268.27 /

+0.14 (+0.05%)

03/10/22 Benchmark
Coherent, MKS, ASML may be impacted by neon supply from Ukraine, says Benchmark
01/03/22 Raymond James
II-VI upgraded to Outperform from Market Perform at Raymond James
12/13/21 Cowen
II-VI named a best idea for 2022 at Cowen
11/08/21 Northland
NeoPhotonics downgraded to Market Perform from Outperform at Northland
IIVI II-VI
$53.29 /

-2.8 (-4.99%)

05/17/22 Piper Sandler
Piper moves to 'more positive stance' on semiconductor stocks
05/10/22 Raymond James
II-VI price target raised to $82 from $79 at Raymond James
04/14/22 Craig-Hallum
II-VI price target lowered to $85 from $100 at Craig-Hallum
02/11/22 Canaccord
II-VI price target lowered to $88 from $104 at Canaccord
OMCL Omnicell
$120.33 /

-3.74 (-3.01%)

IIVI II-VI
$53.29 /

-2.8 (-4.99%)

COHR Coherent
$268.27 /

+0.14 (+0.05%)

COHR Coherent
$268.27 /

+0.14 (+0.05%)

OMCL Omnicell
$120.33 /

-3.74 (-3.01%)

COHR Coherent
$268.27 /

+0.14 (+0.05%)

Conference/Events
Piper Sandler healthcare IT analyst to hold an analyst/industry conference call » 15:25
06/28/22
06/28
15:25
06/28/22
15:25
BDX

Becton Dickinson

$245.03 /

-4.96 (-1.98%)

, OMCL

Omnicell

$120.20 /

-3.87 (-3.12%)

Healthcare IT and…

Healthcare IT and Delivery Analyst Tassan, along with Key Opinion Leader, Dr. Katie McKinney, Pharmacy Director for University of Cincinnati Health, working with Becton, Dickinson & Co. (BDX) & Omnicell (OMCL), discuss hospital capex budgets, spending priorities, supply chain, inventory management/dispensing software, central pharmacy dispensing technology and the 340B program on an Analyst/Industry conference call to be held on June 28 at 4 pm.

ShowHide Related Items >><<
OMCL Omnicell
$120.20 /

-3.87 (-3.12%)

BDX Becton Dickinson
$245.03 /

-4.96 (-1.98%)

BDX Becton Dickinson
$245.03 /

-4.96 (-1.98%)

06/24/22 Wells Fargo
Wells Fargo upgrades 'excellent defensive name' Becton Dickinson to buy
06/24/22 Wells Fargo
Becton Dickinson upgraded to Overweight from Equal Weight at Wells Fargo
06/21/22 BofA
Embecta initiated with an Underperform at BofA
06/06/22 Stifel
Becton's Parata deal 'another positive step forward,' says Stifel
OMCL Omnicell
$120.20 /

-3.87 (-3.12%)

06/16/22 Wells Fargo
Samsung procurement order halt 'positive' for Omnicell, says Wells Fargo
05/03/22 Wells Fargo
Omnicell price target lowered to $158 from $188 at Wells Fargo
05/02/22 Piper Sandler
Omnicell price target lowered to $162 from $181 at Piper Sandler
02/16/22 Wells Fargo
Omnicell price target lowered to $188 from $203 at Wells Fargo
OMCL Omnicell
$120.20 /

-3.87 (-3.12%)

BDX Becton Dickinson
$245.03 /

-4.96 (-1.98%)

OMCL Omnicell
$120.20 /

-3.87 (-3.12%)

BDX Becton Dickinson
$245.03 /

-4.96 (-1.98%)

BDX Becton Dickinson
$245.03 /

-4.96 (-1.98%)

Conference/Events
Piper Sandler healthcare IT analyst to hold an analyst/industry conference call » 04:55
06/28/22
06/28
04:55
06/28/22
04:55
BDX

Becton Dickinson

$249.99 /

-0.57 (-0.23%)

, OMCL

Omnicell

$124.01 /

+2.42 (+1.99%)

Healthcare IT and…

Healthcare IT and Delivery Analyst Tassan, along with Key Opinion Leader, Dr. Katie McKinney, Pharmacy Director for University of Cincinnati Health, working with Becton, Dickinson & Co. (BDX) & Omnicell (OMCL), discuss hospital capex budgets, spending priorities, supply chain, inventory management/dispensing software, central pharmacy dispensing technology and the 340B program on an Analyst/Industry conference call to be held on June 28 at 4 pm.

ShowHide Related Items >><<
OMCL Omnicell
$124.01 /

+2.42 (+1.99%)

BDX Becton Dickinson
$249.99 /

-0.57 (-0.23%)

BDX Becton Dickinson
$249.99 /

-0.57 (-0.23%)

06/24/22 Wells Fargo
Wells Fargo upgrades 'excellent defensive name' Becton Dickinson to buy
06/24/22 Wells Fargo
Becton Dickinson upgraded to Overweight from Equal Weight at Wells Fargo
06/21/22 BofA
Embecta initiated with an Underperform at BofA
06/06/22 Stifel
Becton's Parata deal 'another positive step forward,' says Stifel
OMCL Omnicell
$124.01 /

+2.42 (+1.99%)

06/16/22 Wells Fargo
Samsung procurement order halt 'positive' for Omnicell, says Wells Fargo
05/03/22 Wells Fargo
Omnicell price target lowered to $158 from $188 at Wells Fargo
05/02/22 Piper Sandler
Omnicell price target lowered to $162 from $181 at Piper Sandler
02/16/22 Wells Fargo
Omnicell price target lowered to $188 from $203 at Wells Fargo
OMCL Omnicell
$124.01 /

+2.42 (+1.99%)

BDX Becton Dickinson
$249.99 /

-0.57 (-0.23%)

OMCL Omnicell
$124.01 /

+2.42 (+1.99%)

BDX Becton Dickinson
$249.99 /

-0.57 (-0.23%)

BDX Becton Dickinson
$249.99 /

-0.57 (-0.23%)

Monday
Conference/Events
Piper Sandler healthcare IT analyst to hold an analyst/industry conference call » 15:51
06/27/22
06/27
15:51
06/27/22
15:51
BDX

Becton Dickinson

$249.66 /

-0.9 (-0.36%)

, OMCL

Omnicell

$123.91 /

+2.32 (+1.91%)

Healthcare IT and…

Healthcare IT and Delivery Analyst Tassan, along with Key Opinion Leader, Dr. Katie McKinney, Pharmacy Director for University of Cincinnati Health, working with Becton, Dickinson & Co. (BDX) & Omnicell (OMCL), discuss hospital capex budgets, spending priorities, supply chain, inventory management/dispensing software, central pharmacy dispensing technology and the 340B program on an Analyst/Industry conference call to be held on June 28 at 4 pm.

ShowHide Related Items >><<
OMCL Omnicell
$123.91 /

+2.32 (+1.91%)

BDX Becton Dickinson
$249.66 /

-0.9 (-0.36%)

BDX Becton Dickinson
$249.66 /

-0.9 (-0.36%)

06/24/22 Wells Fargo
Wells Fargo upgrades 'excellent defensive name' Becton Dickinson to buy
06/24/22 Wells Fargo
Becton Dickinson upgraded to Overweight from Equal Weight at Wells Fargo
06/21/22 BofA
Embecta initiated with an Underperform at BofA
06/06/22 Stifel
Becton's Parata deal 'another positive step forward,' says Stifel
OMCL Omnicell
$123.91 /

+2.32 (+1.91%)

06/16/22 Wells Fargo
Samsung procurement order halt 'positive' for Omnicell, says Wells Fargo
05/03/22 Wells Fargo
Omnicell price target lowered to $158 from $188 at Wells Fargo
05/02/22 Piper Sandler
Omnicell price target lowered to $162 from $181 at Piper Sandler
02/16/22 Wells Fargo
Omnicell price target lowered to $188 from $203 at Wells Fargo
OMCL Omnicell
$123.91 /

+2.32 (+1.91%)

BDX Becton Dickinson
$249.66 /

-0.9 (-0.36%)

OMCL Omnicell
$123.91 /

+2.32 (+1.91%)

BDX Becton Dickinson
$249.66 /

-0.9 (-0.36%)

BDX Becton Dickinson
$249.66 /

-0.9 (-0.36%)

Over a week ago
Recommendations
Samsung procurement order halt 'positive' for Omnicell, says Wells Fargo » 12:23
06/16/22
06/16
12:23
06/16/22
12:23
OMCL

Omnicell

$109.92 /

-3.2 (-2.83%)

Wells Fargo analyst Stan…

Wells Fargo analyst Stan Berenshteyn tells investors in a research note that the report that Samsung (SSNLF) has temporarily suspended procurement orders from suppliers due to "swelling inventories and global inflation concerns" is "directionally positive" for Omnicell (OMCL) heading into 2023. The analyst, who made no change to his Overweight rating or $158 price target, believes this news could be an early signal that semiconductor pressures may ease in 2023, which could help Omnicell both secure the necessary supply and potentially do it at lower costs.

ShowHide Related Items >><<
OMCL Omnicell
$109.92 /

-3.2 (-2.83%)

OMCL Omnicell
$109.92 /

-3.2 (-2.83%)

05/03/22 Wells Fargo
Omnicell price target lowered to $158 from $188 at Wells Fargo
05/02/22 Piper Sandler
Omnicell price target lowered to $162 from $181 at Piper Sandler
02/16/22 Wells Fargo
Omnicell price target lowered to $188 from $203 at Wells Fargo
02/15/22 Piper Sandler
Omnicell should be bought on guidance selloff, says Piper Sandler
OMCL Omnicell
$109.92 /

-3.2 (-2.83%)

OMCL Omnicell
$109.92 /

-3.2 (-2.83%)

Over a month ago
Hot Stocks
Omnicell discloses IT systems impacted by ransomware » 08:47
05/09/22
05/09
08:47
05/09/22
08:47
OMCL

Omnicell

$115.46 /

+3.12 (+2.78%)

In a regulatory filing,…

In a regulatory filing, Omnicell disclosed that on May 4, the company determined that certain of its information technology systems were affected by ransomware impacting certain internal systems. "Based on the company's assessment to date, there is no known disruption in the operation of our customers' medication management devices, including automated dispensing systems or robotic equipment. At this time there is an impact on certain of our other products and services. There is also an impact on certain of our internal systems at this time. Security is a top priority for Omnicell, and the company continues to work to take a series of measures to safeguard the integrity of its information technology systems. Upon detecting the security event, the company took immediate steps designed to contain the incident and implement its business continuity plans to restore and support continued operations. The company has notified appropriate law enforcement authorities. The company is also working closely with cybersecurity experts and legal counsel. The company is in the early stages of its investigation and assessment of the security event and cannot determine, at this time, the extent of the impact from such event on our business, results of operations or financial condition or whether such impact will have a material adverse effect," the filing stated.

ShowHide Related Items >><<
OMCL Omnicell
$115.46 /

+3.12 (+2.78%)

OMCL Omnicell
$115.46 /

+3.12 (+2.78%)

05/03/22 Wells Fargo
Omnicell price target lowered to $158 from $188 at Wells Fargo
05/02/22 Piper Sandler
Omnicell price target lowered to $162 from $181 at Piper Sandler
02/16/22 Wells Fargo
Omnicell price target lowered to $188 from $203 at Wells Fargo
02/15/22 Piper Sandler
Omnicell should be bought on guidance selloff, says Piper Sandler
OMCL Omnicell
$115.46 /

+3.12 (+2.78%)

OMCL Omnicell
$115.46 /

+3.12 (+2.78%)

Recommendations
Omnicell price target lowered to $158 from $188 at Wells Fargo » 06:58
05/03/22
05/03
06:58
05/03/22
06:58
OMCL

Omnicell

$115.00 /

+6.24 (+5.74%)

Wells Fargo analyst Stan…

Wells Fargo analyst Stan Berenshteyn lowered the firm's price target on Omnicell to $158 from $188 and keeps an Overweight rating on the shares following Q1 results. Though management reiterated its revenue and adjusted EBITDA guidance for 2022 despite the Q1 beat, the analyst brought down his EBITDA estimates somewhat for the following year, as he contemplates persistence to inflation/supply chain headwinds as well as some decremental volume considerations related to Omnicell's 340B asset.

ShowHide Related Items >><<
OMCL Omnicell
$115.00 /

+6.24 (+5.74%)

OMCL Omnicell
$115.00 /

+6.24 (+5.74%)

05/02/22 Piper Sandler
Omnicell price target lowered to $162 from $181 at Piper Sandler
02/16/22 Wells Fargo
Omnicell price target lowered to $188 from $203 at Wells Fargo
02/15/22 Piper Sandler
Omnicell should be bought on guidance selloff, says Piper Sandler
12/06/21 Wells Fargo
Omnicell initiated with an Overweight at Wells Fargo
OMCL Omnicell
$115.00 /

+6.24 (+5.74%)

OMCL Omnicell
$115.00 /

+6.24 (+5.74%)

Recommendations
Omnicell price target lowered to $162 from $181 at Piper Sandler » 16:04
05/02/22
05/02
16:04
05/02/22
16:04
OMCL

Omnicell

$115.03 /

+6.27 (+5.76%)

Piper Sandler analyst…

Piper Sandler analyst Sean Wieland lowered the firm's price target on Omnicell to $162 from $181 and keeps an Overweight rating on the shares. The company last week reported Q1 revenue, adjusted EBITDA and adjusted earnings above the high end of guidance despite challenges in 340B and delayed maintenance renewals, Wieland tells investors in a research note. The analyst says the results "testify to the resilience of OMCL's diversified platform and agile operating structure." He thinks regulatory catalysts will drive accelerating growth within specialty pharmacy and IV compounding over the next 24 months.

ShowHide Related Items >><<
OMCL Omnicell
$115.03 /

+6.27 (+5.76%)

OMCL Omnicell
$115.03 /

+6.27 (+5.76%)

02/16/22 Wells Fargo
Omnicell price target lowered to $188 from $203 at Wells Fargo
02/15/22 Piper Sandler
Omnicell should be bought on guidance selloff, says Piper Sandler
12/06/21 Wells Fargo
Omnicell initiated with an Overweight at Wells Fargo
12/02/21 Piper Sandler
Piper remains buyer of Omnicell after management meeting
OMCL Omnicell
$115.03 /

+6.27 (+5.76%)

OMCL Omnicell
$115.03 /

+6.27 (+5.76%)

Earnings
Omnicell raises FY22 EPS view to $3.85-$4.05 from $3.75-$3.95 » 16:05
04/28/22
04/28
16:05
04/28/22
16:05
OMCL

Omnicell

$107.02 /

-1.1 (-1.02%)

Consensus $3.67. Narrows…

Consensus $3.67. Narrows FY22 revenue view to $1.385B-$1.41B from $1.37B-$1.43B, consensus $1.4B.

ShowHide Related Items >><<
OMCL Omnicell
$107.02 /

-1.1 (-1.02%)

OMCL Omnicell
$107.02 /

-1.1 (-1.02%)

02/16/22 Wells Fargo
Omnicell price target lowered to $188 from $203 at Wells Fargo
02/15/22 Piper Sandler
Omnicell should be bought on guidance selloff, says Piper Sandler
12/06/21 Wells Fargo
Omnicell initiated with an Overweight at Wells Fargo
12/02/21 Piper Sandler
Piper remains buyer of Omnicell after management meeting
OMCL Omnicell
$107.02 /

-1.1 (-1.02%)

OMCL Omnicell
$107.02 /

-1.1 (-1.02%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.